Objective: The purpose of this study was to evaluate the extent to which treatment effect on magnetic resonance imaging (MRI)-derived measures of brain atrophy and focal lesions can mediate, at the trial level, the treatment effect on cognitive outcomes in multiple sclerosis (MS).Methods: We collected all published randomized clinical trials in...
-
2023 (v1)PublicationUploaded on: January 31, 2024
-
2017 (v1)Publication
Baseline brain volume (BV) is predictive at a group level but is difficult to interpret at the single patient level.
Uploaded on: April 14, 2023 -
2017 (v1)Publication
To predict long-term disability outcomes in TEMSO core (NCT00134563) and extension (NCT00803049) studies in patients with relapsing forms of MS treated with teriflunomide. Methods: A post hoc analysis was conducted in a subgroup of patients who received teriflunomide in the core study, had MRI and clinical relapse assessments at months 12 (n =...
Uploaded on: April 14, 2023 -
2023 (v1)Publication
This review analyzes the role of TNF-alpha and its increase in biological fluids in mild cognitive impairment, and Alzheimer's disease (AD). The potential inhibition of TNF-alpha with pharmacological strategies paves the way for preventing AD and improving cognitive function in people at risk for dementia. We conducted a narrative review to...
Uploaded on: March 4, 2024 -
2015 (v1)Publication
Therapies that target the underlying pathology of multiple sclerosis (MS), including focal and diffuse damage, may improve long-term disease control. Focal damage (inflammatory lesions) manifests clinically mainly as relapses, whereas diffuse damage (neurodegeneration and brain volume loss) has been more closely associated with disability...
Uploaded on: March 27, 2023 -
2022 (v1)PublicationSecondary Prevention in Radiologically Isolated Syndromes and Prodromal Stages of Multiple Sclerosis
Following the extraordinary progress in the treatment of multiple sclerosis (MS), two major unmet needs remain: understanding the etiology of the disease and, hence, designing definitive cures (this perspective is neither at hand, nor it can be taken for granted that the etiologic targets will be readily treatable); the prevention of an overt...
Uploaded on: February 14, 2024 -
2016 (v1)Publication
The variability in the severity and clinical course of multiple sclerosis (MS) has as its basis an extreme heterogeneity in the location, nature and extent of pathology in the brain and spinal cord. Understanding the underlying neuropathology and associated pathogenetic mechanisms of the disease helps to communicate the rationale for treatment...
Uploaded on: April 14, 2023